Search

everythinglearnresearchcommunity

for

Search:↓

A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.

Stopping adalimumab and starting methotrexate with topical treatments improved the woman's scalp psoriasis and hair regrew.

ALA-PDT is effective and safe for chronic X-ray dermatitis, providing complete or partial remission.

New treatments for skin conditions show promise, especially Coacillium® for hair growth in young people with alopecia areata.

New treatments targeting T-cell pathways are needed for better alopecia areata management.

Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.

Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.

A patient with PPP had rare skin reactions to adalimumab, which improved after stopping smoking and continuing acitretin.

Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.

Combining gemcitabine with paclitaxel is more effective than with pemetrexed for advanced lung cancer.

Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.

Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

A patient with a new PLEC gene mutation showed symptoms of both muscular dystrophy and myasthenia gravis, which improved with steroid treatment.

Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.

Baricitinib shows promise in treating severe hair loss.

Abemaciclib can cause skin, hair, and nail problems, leading some patients to stop using it.

Dupilumab helped a woman with severe hair loss regrow her hair quickly and maintain it for six months after stopping treatment.

Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.

Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.

Enhancing Tregs can protect against alopecia areata.

Baricitinib at 2mg and 4mg doses improved work productivity and reduced costs for adults with atopic dermatitis.

Dimethyl fumarate speeds up wound healing in IL-36Ra deficient mice by reducing NET formation and oxidative stress.

Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.

Dupilumab for eczema may cause hair loss.

Oral baricitinib is effective and safe for treating alopecia areata.

Ritlecitinib shows promise for hair regrowth in alopecia areata patients.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

Dupilumab may cause hair loss in some patients with severe atopic dermatitis.

Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.